Advanced in Lung Metastases

Toyoaki Hida

Minokamo, JP 
Advanced in Lung Metastases
Minokamo, JP 
OverviewLocationsClinical Research

Overview

Toyoaki Hida practices in Minokamo, Japan. Hida is rated as an Advanced expert by MediFind in the treatment of Lung Metastases. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy.

Their clinical research consists of co-authoring 164 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles in the study of Lung Metastases.

Locations

Minokamo, Japan
Other Locations
Nagoya, Japan
Okazaki, Japan
Gifu-shi, Japan
Tokyo, Japan
Sapporo, 0608543, Japan
Chikusa, Japan
Higashi, 8128582, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2
View 1 Less Clinical Trial

164 Total Publications

Cerebrospinal fluid cytology for the diagnosis of lung cancer brain metastasis: a case report.
Cerebrospinal fluid cytology for the diagnosis of lung cancer brain metastasis: a case report.
Journal: Translational lung cancer research
Published: January 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hida's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile